Powered by

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Mar 22, 2017 - Thomson Reuters ONE

PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares ("ADSs") at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 ADSs at the public offerin...